低风险TAVR试验——对当前形势的关键评估。

IF 3.5 2区医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS

American heart journal Pub Date : 2025-07-29 DOI:10.1016/j.ahj.2025.07.070

Troels Højsgaard Jørgensen MD, PhD , Hans Gustav Hørsted Thyregod MD, PhD , Stefan Blankenberg MD, PhD , Martin Leon MD , Lars Sondergaard MD, DMSc , Bernard Prendergast MD, PhD , Ole De Backer MD, PhD

{"title":"低风险TAVR试验——对当前形势的关键评估。","authors":"Troels Højsgaard Jørgensen MD, PhD , Hans Gustav Hørsted Thyregod MD, PhD , Stefan Blankenberg MD, PhD , Martin Leon MD , Lars Sondergaard MD, DMSc , Bernard Prendergast MD, PhD , Ole De Backer MD, PhD","doi":"10.1016/j.ahj.2025.07.070","DOIUrl":null,"url":null,"abstract":"<div><div>The low-risk TAVR vs SAVR RCTs - PARTNER-3, Evolut Low-Risk, DEDICATE, and NOTION-2 - demonstrate that TAVR is at least as effective as SAVR in terms of early mortality and disabling stroke, although outcomes varied across studies. The excellent outcomes observed in the PARTNER-3 trial reflect the highly selected patient population, while the NOTION-2 trial highlights the challenges posed by anatomical variations, such as bicuspid aortic valves (AV). These findings highlight the importance of a personalized approach guided by a multidisciplinary Heart Team, taking into account both clinical and anatomical aspects when choosing between TAVR and SAVR.</div><div>Trial registration number: ClinicalTrials.gov NCT02825134.</div></div>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":"291 ","pages":"Pages 10-13"},"PeriodicalIF":3.5000,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The low-risk TAVR trials—A critical appraisal of the current landscape\",\"authors\":\"Troels Højsgaard Jørgensen MD, PhD , Hans Gustav Hørsted Thyregod MD, PhD , Stefan Blankenberg MD, PhD , Martin Leon MD , Lars Sondergaard MD, DMSc , Bernard Prendergast MD, PhD , Ole De Backer MD, PhD\",\"doi\":\"10.1016/j.ahj.2025.07.070\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>The low-risk TAVR vs SAVR RCTs - PARTNER-3, Evolut Low-Risk, DEDICATE, and NOTION-2 - demonstrate that TAVR is at least as effective as SAVR in terms of early mortality and disabling stroke, although outcomes varied across studies. The excellent outcomes observed in the PARTNER-3 trial reflect the highly selected patient population, while the NOTION-2 trial highlights the challenges posed by anatomical variations, such as bicuspid aortic valves (AV). These findings highlight the importance of a personalized approach guided by a multidisciplinary Heart Team, taking into account both clinical and anatomical aspects when choosing between TAVR and SAVR.</div><div>Trial registration number: ClinicalTrials.gov NCT02825134.</div></div>\",\"PeriodicalId\":7868,\"journal\":{\"name\":\"American heart journal\",\"volume\":\"291 \",\"pages\":\"Pages 10-13\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2025-07-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American heart journal\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0002870325002881\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American heart journal","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0002870325002881","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

摘要

低风险TAVR与SAVR的随机对照试验——PARTNER-3、Evolut low-risk、dedicated和concept -2——表明，在早期死亡率和致残性卒中方面，TAVR至少与SAVR一样有效，尽管不同研究的结果不同。PARTNER-3试验中观察到的良好结果反映了高度选择性的患者群体，而noon -2试验强调了解剖变异带来的挑战，如双尖瓣主动脉瓣。这些发现强调了由多学科心脏团队指导的个性化方法的重要性，在选择TAVR或SAVR时考虑到临床和解剖学方面。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The low-risk TAVR trials—A critical appraisal of the current landscape

The low-risk TAVR vs SAVR RCTs - PARTNER-3, Evolut Low-Risk, DEDICATE, and NOTION-2 - demonstrate that TAVR is at least as effective as SAVR in terms of early mortality and disabling stroke, although outcomes varied across studies. The excellent outcomes observed in the PARTNER-3 trial reflect the highly selected patient population, while the NOTION-2 trial highlights the challenges posed by anatomical variations, such as bicuspid aortic valves (AV). These findings highlight the importance of a personalized approach guided by a multidisciplinary Heart Team, taking into account both clinical and anatomical aspects when choosing between TAVR and SAVR.

Trial registration number: ClinicalTrials.gov NCT02825134.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

American heart journal 医学-心血管系统

CiteScore

8.20

自引率

2.10%

发文量

214

审稿时长

38 days

期刊介绍： The American Heart Journal will consider for publication suitable articles on topics pertaining to the broad discipline of cardiovascular disease. Our goal is to provide the reader primary investigation, scholarly review, and opinion concerning the practice of cardiovascular medicine. We especially encourage submission of 3 types of reports that are not frequently seen in cardiovascular journals: negative clinical studies, reports on study designs, and studies involving the organization of medical care. The Journal does not accept individual case reports or original articles involving bench laboratory or animal research.